Loading...
Docoh

Pieris Pharmaceuticals (PIRS)

News

From Benzinga Pro
4 Stocks Under $3 Insiders Are Aggressively Buying
17 May 22
Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas
US crude oil futures traded slightly lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
11 May 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: Pieris Pharmaceuticals Q1 Earnings
11 May 22
Earnings, News
Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Pieris Pharmaceuticals Q1 EPS $(0.07) Beats $(0.11) Estimate, Sales $10.99M Miss $11.30M Estimate
11 May 22
Earnings, News
Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is unchanged from the same period last year. The company
Earnings Scheduled For May 11, 2022
11 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Pieris Pharmaceuticals's Earnings Outlook
10 May 22
Earnings
Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Pieris Pharmaceuticals will report an earnings per share (EPS) of $-0.11.
Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed
4 Mar 22
Earnings
According to Benzinga Pro data, during Q4, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $8.44 million. Earnings were up 42.36%, but Pieris Pharmaceuticals still reported an overall loss of $9.53 million.
Recap: Pieris Pharmaceuticals Q4 Earnings
1 Mar 22
Earnings, News
Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Earnings Scheduled For March 1, 2022
1 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter.
Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group?
28 Feb 22
Penny Stocks, Small Cap, Trading Ideas
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

Press releases

From Benzinga Pro
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
18 May 22
Biotech, Events, Press Releases
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
11 May 22
Biotech, Earnings, Press Releases
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDTBOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
4 May 22
Biotech, News, Press Releases
BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for
ONK Therapeutics Brings in US Financial Experience with the Appointment of Dr. Allan Reine as Independent Non-Executive Director
23 Mar 22
Press Releases
Allan Reine joins the Board as independent Non-Executive Director Brings significant experience as CFO of NASDAQ-listed biotechs, where he helped raise over $700 million Over 20 years in the biotechnology industry with
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
1 Mar 22
Biotech, Earnings, Press Releases
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM ESTInitiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this yearDosed first patient in phase 2 gastric
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
23 Feb 22
Biotech, News, Press Releases
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform